This session provides a comprehensive analysis of the recent financial growth and evolving ecosystem of regenerative medicine and cell/gene therapy (CGT) in Japan, benchmarked against other regional markets. Key discussion points include current market trends, regulatory pathways, successfully approved products, CMC strategies, automation, and advanced analytical technologies. The session will also explore Japan’s unique challenges with non-reimbursed (private) treatments and the subsequent shifts in its regulatory landscape.
